Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Misako Nagasaka, MD PhD"'
Autor:
Shannon S. Zhang, MD, Alexa B. Schrock, PhD, Misako Nagasaka, MD PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100453- (2023)
Externí odkaz:
https://doaj.org/article/42bf59772e3b4a79b0a1df9d44054573
Autor:
Shannon S. Zhang, MD, Jessica K. Lee, MSc, Hanna Tukachinsky, PhD, Alexa B. Schrock, PhD, Misako Nagasaka, MD, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100387- (2022)
Introduction: Germline CHEK2 mutations are rare and have not been associated with increased risk of NSCLC. Methods: We identified two sequential primary NSCLCs harboring distinct actionable driver alterations (EGFR E746 _S752 delinsV and CD74-ROS1) i
Externí odkaz:
https://doaj.org/article/e5774861fb6d4b509b5508a9a6e29a18
Autor:
So Yeon Kim, MD, Jun Yin, MD, Stephen Bohlman, MD, PhD, Phillip Walker, PhD, Sanja Dacic, MD, PhD, Chul Kim, MD, Hina Khan, MD, Stephen V. Liu, MD, Patrick C. Ma, MD, Misako Nagasaka, MD, PhD, Karen L. Reckamp, MD, Jim Abraham, PhD, Dipesh Uprety, MD, Feng Wang, PhD, Joanne Xiu, PhD, Jian Zhang, PhD, Haiying Cheng, MD, PhD, Balazs Halmos, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100381- (2022)
Introduction: Genomic alterations in the juxtamembrane exon 14 splice sites in NSCLC lead to increased MET stability and oncogenesis. We present the largest cohort study of MET Exon 14 (METex14) using whole transcriptome sequencing. Methods: A total
Externí odkaz:
https://doaj.org/article/57c16c1c6a93496da63baca1c937d2d4
Autor:
Kaleem Anwar, PharmD, Lee Nguyen, PharmD, Misako Nagasaka, MD, PhD, Sai-Hong Ignatius Ou, MD, PhD, Alexandre Chan, PharmD, MPH
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100452- (2023)
Introduction: Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be promising in the treatment of coronavirus disease 2019. The active antiviral component nirmatrelvir in Paxlovid is co-formulated with ritonavir, a strong c
Externí odkaz:
https://doaj.org/article/f80c0980bd8441c8a8ab68fda6612021